UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
March 11, 2004
Date of Report (Date of earliest event reported)
NPS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 0-23272 | 87-0439579 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
420 Chipeta Way
Salt Lake City, Utah 84108
(Address of Principal Executive Offices)
(801) 583-4939
(Registrant’s Telephone Number, Including Area Code)
ITEM 5: Other Events
On March 8, 2004, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 11, 2004 | NPS PHARMACEUTICALS, INC. | |||
By: | /S/ HUNTER JACKSON | |||
Hunter Jackson | ||||
CEO, President and Chairman of the Board |
EXHIBIT INDEX
Exhibit Number | Description | |
99.1 | Press Release issued by NPS Pharmaceuticals, Inc. on March 8, 2004 announcing approval of Sensipar(TM) by U.S. FDA. |